S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically or pathologically confirmed ovarian epithelial, primary peritoneal, or fallopian tube cancer
• * No mixed mullerian and borderline ovarian tumors
• Surgically staged as stage III or IV at initial diagnosis
• Must meet one of the following criteria for refractory/relapsed disease:
• * Relapsed within 6 months after completing front-line concurrent or sequential platinum (either cisplatin or carboplatin) and taxane (paclitaxel or docetaxel) chemotherapy
• * Had a best response of increasing disease during this front-line regimen
• * Consolidation chemotherapy and reinduction therapy are counted as part of the front-line regimen
• Unidimensionally measurable disease
• * At least 2 cm by medical photograph (skin or oral lesion), palpation, plain x-ray, CT scan, MRI, or other conventional technique (bone lesions not included)
• * At least 1 cm by spiral CT scan
• * Measurable disease must remain outside of radiotherapy field
• If the tumor is known to be KIT (CD117) or PDGFR positive, patient must be offered SWOG-S0211 if available
• PATIENT CHARACTERISTICS:
• Age
• Not specified
• Performance status
• Zubrod 0-2
• Life expectancy
• Not specified
• Hematopoietic
• Not specified
• Hepatic
• Not specified
• Renal
• Not specified
• Cardiovascular
• No myocardial infarction within the past 6 months
• No angina pectoris
• No uncontrolled congestive heart failure
• No uncontrolled cardiac arrhythmia
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No other malignancy within the past 5 years except for the following:
• * Adequately treated basal cell or squamous cell skin cancer
• * Carcinoma in situ of the cervix
• * Adequately treated stage I or II cancer from which the patient is currently in complete remission
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• No more than 1 prior biological response modifier
• At least 28 days since prior biological response modifier and recovered
• Chemotherapy
• See Disease Characteristics
• No prior topotecan or other topoisomerase I inhibitor
• One other additional prior chemotherapy regimen allowed
• At least 28 days since prior chemotherapy (14 days for weekly chemotherapy) and recovered
• Endocrine therapy
• Prior hormonal therapy allowed
• No concurrent hormonal therapy
• Radiotherapy
• At least 28 days since prior radiotherapy and recovered
• No prior radiotherapy to more than 25% of bone marrow
• No concurrent palliative radiotherapy
• Surgery
• At least 14 days since prior major surgery and recovered
• Other
• At least 28 days since prior investigational drugs and recovered
• No other concurrent antitumor therapy